According to Expression Analysis, the Geneblitz unit offers molecular services to pharmaceutical companies, governmental agencies, universities and research institutes. The partnership will give Expression Analysis access to these clients and will allow both companies to expand their service offerings.
Steve McPhail, president and CEO of Expression Analysis, said: “The partnership with Geneblitz provides us an established presence in the UK, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms.”
Louise Allcroft, CEO of Complement Genomics, said: “Expression Analysis is an industry leader with a great reputation in the field of genomic services and our decision to partner with them was not a difficult one. By combining our experience, scientific leadership and high-throughput capabilities, we will be able to help meet the needs of the extensive pharmaceutical and biotechnology infrastructure in the UK.”